Login / Signup

Preclinical safety assessment of pathogen reduced red blood cells treated with amustaline and glutathione.

Anne K NorthNina MuftiTheresa SullivanLaurence M Corash
Published in: Transfusion (2020)
PR-RBCCs did not demonstrate genotoxicity in vitro or in vivo and were not carcinogenic in vivo. These studies support the safety of PR-RBCCs and suggest that there is no measurable genotoxic hazard associated with transfusion of PR-RBCCs.
Keyphrases
  • red blood cell
  • cardiac surgery
  • sickle cell disease
  • polycyclic aromatic hydrocarbons
  • bone marrow
  • mesenchymal stem cells